Patent · US Active

Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators

US7960380B2 · kind B2 · utility

0Cited by

0References

17Claims

0Family size

Assignee

ASTRAZENECA AB · SE

Inventors

Anders Broo · Timrå, SE
Robert Judkins · Mölndal, SE
Lanna Li · Timrå, SE
Eva-Lotte Lindstedt-Alstermark · Mölndal, SE
Pernilla Sandberg · Timrå, SE
Marianne Swanson · Gothenburg, SE
Lars Weidolf · Timrå, SE
Kay Brickmann · Timrå, SE
Patrik Holm · Vaasa, FI

Key dates

Filing date	Mar 17, 2010
Grant date	Jun 14, 2011
Priority date	—
Expiry date	Mar 17, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.